Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other brokerages have also issued reports on ENTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Enanta Pharmaceuticals Stock Up 0.9%

ENTA stock opened at $12.96 on Friday. The firm has a market cap of $377.40 million, a PE ratio of -5.38 and a beta of 0.96. The business has a 50 day moving average of $13.13 and a 200-day moving average of $13.29. Enanta Pharmaceuticals has a 12-month low of $10.12 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $14.36 million for the quarter, compared to analysts’ expectations of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. On average, research analysts expect that Enanta Pharmaceuticals will post -2.36 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP purchased a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $36,000. Legal & General Group Plc bought a new position in Enanta Pharmaceuticals during the second quarter worth about $41,000. Clearstead Trust LLC purchased a new position in shares of Enanta Pharmaceuticals in the second quarter worth about $74,000. Kingsview Wealth Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth about $168,000. Finally, Bank of America Corp DE bought a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $314,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.